|
[1]
|
Koo, E.H., Lansbury, P.T. and Kelly, J.W. (1999) Amyloid Diseases: Abnormal Protein Aggregation in Neurodegeneration. Pro-ceedings of the National Academy of Sciences of the United States of America, 96, 9989.
[Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Organization, W.H. (2012) Dementia: A Public Health Priority. Perspect Public Health, 5, 123-125.
|
|
[3]
|
Hardy, J. (2000) Pathways to Primary Neurodegenerative Disease. Neurologia, 924, 29-34.
[Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Evans, D.A., Funkenstein, H.H., Albert, M.S., et al. (1989) Prevalence of Alzheimer’s Disease in a Community Population of Older Persons. Higher than Previously Reported. JAMA, 262, 2551-2556.
[Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Selkoe, D.J. (2002) Alzheimer’s Disease Is a Synaptic Failure. Science, 298, 789.
[Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Walsh, D.M. and Selkoe, D.J. (2004) Deciphering the Molecular Basis of Memory Failure in Alzheimer’s Disease. Neuron, 44, 181-193.
[Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Butterfield, D.A., Reed, T., Newman, S.F., et al. (2007) Roles of Amyloid β-Peptide-Associated Oxidative Stress and Brain Protein Modifications in the Pathogenesis of Alzheimer's Disease and Mild Cognitive Impairment. Free Radical Biology & Medicine, 43, 658-677.
[Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Woo, H.N., Park, J.S., Gwon, A.R., et al. (2009) Alzheimer's Disease and Notch Signaling. Biochemical & Biophysical Research Communications, 390, 1093-1097.
[Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Huang, X., Moir, R.D., Tanzi, R.E., et al. (2004) Redox-Active Metals, Oxida-tive Stress, and Alzheimer’s Disease Pathology. Annals of the New York Academy of Sciences, 1012, 153.
[Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Clark, T.A., Pil, L.H., Rolston, R.K., et al. (2010) Oxidative Stress and its Impli-cations for Future Treatments and Management of Alzheimer Disease. International Journal of Biomedical Science Ijbs, 6, 225.
|
|
[11]
|
Guan, Z. (2008) Cross-Talk between Oxidative Stress and Modifications of Cholinergic and Glutaminergic Receptors in the Pathogenesis of Alzheimer’s Disease. Acta Pharmacologica Sinica, 29, 773-780.
|
|
[12]
|
吕志迈, 徐运. 淀粉样蛋白代谢相关基因与阿尔茨海默病的研究进展[J]. 国际神经病学神经外科学杂志, 2007, 34(6): 527-530.
|
|
[13]
|
黄叶静, 刘协和, 邓红, 王英成, 李胜富. 淀粉样多肽诱导神经元凋亡和氧化应激机制的实验观察[J]. 中华神经科杂志, 2002, 10(4): 250-251.
|
|
[14]
|
Lustbader, J.W., Cirilli, M., Lin, C., Xu, H.W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S. and Chaney, M. (2004) ABAD Directly Links Aβ to Mitochondrial Toxicity in Alzheimer’s Disease. Science, 304, 448-452.
[Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Youn, K., Lee, S., Jeong, W.S., Ho, C.T. and Jun, M. (2016) Protective Role of Corilagin on Aβ25-35-Induced Neurotoxicity: Suppression of NF-κB Signaling Pathway. Journal of Medicinal Food, 19, 901-911.
[Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Chen, Z. and Zhong, C. (2014) Oxidative Stress in Alzheimer’s Disease. Neuros-cience Bulletin, 18, 271-281.
|
|
[17]
|
Sultana, R., Mecocci, P., Mangialasche, F., Cecchetti, R., Baglioni, M. and Butterfield, D.A. (2011) Increased Protein and Lipid Oxidative Damage in Mitochondria Isolated from Lymphocytes from Patients with Alzheimer’s Disease: Insights into the Role of Oxidative Stress in Alzheimer’s Disease and Initial Investigations into a Potential Biomarker for This. Journal of Alzheimer’s Disease, 24, 77-84.
|
|
[18]
|
Che, H., Du, L., Cong, P., Tao, S., Ding, N., Wu, F., Xue, C., Xu, J. and Wang, Y. (2017) Cerebrosides from Sea Cucumber Protect against Oxidative Stress in SAMP8 Mice and PC12 Cells. Journal of Medicinal Food, 20, 392-402.
[Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Fadi, M. and Serge, G. (2010) Update on the Pharmacological Treatment of Alz-heimer’s Disease. Current Neuropharmacology, 8, 69-80.
[Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Soodi, M., Saeidnia, S., Sharifzadeh, M., et al. (2016) Satureja Bachtiarica Ameliorate Beta-Amyloid Induced Memory Impairment, Oxidative Stress and Cholinergic Deficit in Animal Model of Alzheimer’s Disease. Metabolic Brain Disease, 31, 395-404.
[Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Hayeon, J., Jooyoun, K., Hongkyu, L., et al. (2010) Leaf and Stem of Vitis Amurensis and Its Active Components Protect against Amyloid β Protein (25-35)-Induced Neurotoxicity. Archives of Pharmacal Research, 33, 1655-1664.
[Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Guo, X., Sun, G., Zhou, T., et al. (2017) LX2343 Alleviates Cognitive Im-pairments in AD Model Rats by Inhibiting Oxidative Stress-Induced Neuronal Apoptosis and Tauopathy. Acta Pharmacologica Sinica, 38, 1104-1119.
[Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Garciaalloza, M., Borrelli, L.A., Hyman, B.T., et al. (2010) Antioxidants Have a Rapid and Long-Lasting Effect on Neuritic Abnormalities in APP:PS1 Mice. Neurobiology of Aging, 31, 2058-2068.
[Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Liang, W., Zhao, X., Feng, J., et al. (2016) Ursolic Acid Attenuates Beta-Amyloid-Induced Memory Impairment in Mice. Arquivos de Neuro-Psiquiatria, 74, 482-488.
[Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Peters, I., Igbavboa, U., Schütt, T., et al. (2009) The Interaction of Be-ta-Amyloid Protein with Cellular Membranes Stimulates Its Own Production. Biochimica et Biophysica Acta (BBA)—Biomembranes, 1788, 964-972.
[Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Drake, J. (2001) Evidence of Oxidative Damage in Alzheimer’s Disease Brain: Central Role for Amyloid Beta-Peptide. Trends in Molecular Medicine, 7, 548-554.
[Google Scholar] [CrossRef]
|
|
[27]
|
Butterfield, D.A., Castegna, A., Lauderback, C.M., et al. (2015) Evidence That Amyloid Beta-Peptide-Induced Lipid Peroxidation and Its Sequelae in Alzheimer’s Disease Brain Contribute to Neuronal Death. Neurobiology of Aging, 23, 655-664.
[Google Scholar] [CrossRef]
|
|
[28]
|
Yang, P., He, X.Q., Peng, L., et al. (2007) The Role of Oxidative Stress in Hormesis Induced by Sodium Arsenite in Human Embryo Lung Fibroblast (HELF) Cellular Proliferation Model. Journal of Toxicology & Environmental Health Part A, 70, 976-983.
[Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Gandhi, S. and Abramov, A.Y. (2012) Mechanism of Oxidative Stress in Neurodegeneration. Oxidative Medicine and Cellular Longevity, 2012, Article ID: 428010.
[Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Finkel, T. (1999) Signal Transduction by Reactive Oxygen Species. Journal of Cell Biology, 65, 337-340.
|
|
[31]
|
Takuma, K., Yao, J., Huang, J., et al. (2005) ABAD Enhances Aszlig Beta-Induced Cell Stress via Mi-tochondrial Dysfunction. FASEB Journal, 19, 597-598.
[Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Ochoa, J.J., Pamplona, R., Ramirez-Tortosa, M.C., et al. (2011) Age-Related Changes in Brain Mitochondrial DNA Deletion and Oxidative Stress Are Diffe-rentially Modulated by Dietary Fat Type and Coenzyme Q₁₀. Free Radical Biology & Medicine, 50, 1053-1064.
|
|
[33]
|
Innis, S.M. (2005) Essential Fatty Acid Transfer and Fetal Development. Placenta, 26, S70-S75.
|
|
[34]
|
Varadarajan, S., Yatin, S., Aksenova, M., et al. (2000) Review: Alzheimer’s Amyloid β-Peptide-Associated Free Radical Oxidative Stress and Neurotoxicity. Journal of Structural Biology, 130, 184-208.
[Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Mattson, M.P. (2004) Pathways towards and away from Alzheimer’s Disease. Na-ture, 430, 631-639.
[Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Ellis, C.R., Tsai, C.C., Lin, F.Y. and Shen, J. (2017) Conformational Dynamics of Cathepsin D and Binding to a Small-Molecule BACE1 Inhibitor. Journal of Computational Chemistry, 38, 1260-1269.
[Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Yan, R. and Vassar, R. (2014) Targeting the β Secretase BACE1 for Alzheimer’s Disease Therapy. The Lancet Neurology, 13, 319-329.
[Google Scholar] [CrossRef]
|
|
[38]
|
Eikelenboom, P., Zhan, S.S., van Gool, W.A., et al. (1996) Inflammatory Mechanisms in Alzheimer’s Disease. Trends in Pharmacological Sciences, 246, 124-128.
|
|
[39]
|
Mcgeer, P.L. and Mcgeer, E.G. (1995) The Inflammatory Response System of Brain: Implications for Therapy of Alz-heimer and Other Neurodegenerative Diseases. Brain Research Brain Research Reviews, 21, 195-218.
[Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Esposito, G., De, F.D., Maiuri, M.C., et al. (2006) Cannabidiol Inhibits Inducible Nitric Oxide Synthase Protein Expression and Nitric Oxide Production in Beta-Amyloid Stimulated PC12 Neurons through p38 MAP Kinase and NF-kappaB Involvement. Neuroscience Letters, 399, 91-95.
[Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Andressa, B., Frozza, R.L., André, M., et al. (2012) Indomethacin-Loaded Lipid-Core Nanocapsules Reduce the Damage Triggered by Aβ1-42 in Alzheimer’s Disease Models. International Journal of Nano-medicine, 7, 4927-4942.
|
|
[42]
|
Kaltschmidt, B., Uherek, M., Volk, B., et al. (1997) Transcription Factor NF-Kappa B Is Activated in Primary Neurons by Amyloid Beta Peptides and in Neurons Surrounding Early Plaques from Patients with Alzheimer Disease. Pro-ceedings of the National Academy of Sciences of the United States of America, 94, 2642-2647.
[Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Sastre, M., Klockgether, T. and Heneka, M.T. (2006) Contribution of Inflammatory Processes to Alzheimer’s Disease: Molecular Mechanisms. International Journal of Developmental Neuroscience the Official Journal of the International Society for Developmental Neuroscience, 24, 167-176.
[Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Liu, H., Wang, J., Wang, J., et al. (2015) Paeoniflorin Attenuates Aβ1-42-Induced Inflammation and Chemotaxis of Microglia in Vitro and Inhibits NF-κB- and VEGF/Flt-1 Signaling Pathways. Brain Research, 1618, 149-158.
[Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Baker, H., Sidorowicz, A., Sehgal, S.N., et al. (1978) Rapamycin (AY-22,989), a New Antifungal Antibiotic. III. In Vitro and in Vivo Evaluation. Journal of Antibiotics, 31, 539-545.
[Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Huang, K. and Fingar, D.C. (2014) Growing Knowledge of the mTOR Signaling Network. Seminars in Cell & Developmental Biology, 36, 79-90.
[Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Richardson, A., Galvan, V., Lin, A.L., et al. (2015) How Longevity Research Can Lead to Therapies for Alzheimer’s Disease: The Rapamycin Story. Experimental Gerontology, 68, 51-58.
[Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Siman, R., Cocca, R. and Dong, Y. (2015) The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy. PLoS ONE, 10, e0142340.
[Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Liu, Y.C., Gao, X.X., Ling, C., et al. (2017) Rapamycin Suppresses Aβ25-35- or LPS-Induced Neuronal Inflammation via Modulation of NF-κB Signaling. Neuroscience, 355, 188-199.
[Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Huang, H., Chang, H., Tsai, M., et al. (2016) 6-Mercaptopurine Atte-nuates Tumor Necrosis Factor-α Production in Microglia through Nur77-Mediated Transrepression and PI3K/Akt/mTOR Signal-ing-Mediated Translational Regulation. Journal of Neuroinflammation, 13, 78.
[Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Dhingra, R., Gang, H., Wang, Y., et al. (2013) Bidirectional Regulation of Nuclear Factor-κB and Mammalian Target of Rapamycin Signaling Functionally Links Bnip3 Gene Repression and Cell Survival of Ventricular Myocytes. Circulation Heart Failure, 6, 335-343.
[Google Scholar] [CrossRef]
|
|
[52]
|
Mengke, N.S., Hu, B., Han, Q.P., et al. (2016) Rapamycin Inhibits Lipopolysaccharide-Induced Neuroinflammation in Vitro and in Vivo. Molecular Medicine Reports, 14, 4957-4966.
[Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Varnum, M.M. and Ikezu, T. (2012) The Classification of Microglial Activation Phenotypes on Neurodegeneration and Regeneration in Alzheimer’s Disease Brain. Archivum Immunologiae Et Therapiae Experi-mentalis, 60, 251-266.
[Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Weingarten, M.D., Lockwood, A.H., Hwo, S.Y., et al. (1975) A Protein Factor Essential for Microtubule Assembly. Proceedings of the National Academy of Sciences of the United States of America, 72, 1858-1862.
[Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Iqbal, K., Liu, F., Gong, C.X., et al. (2010) Tau in Alzheimer Disease and Related Tauopathies. Current Alzheimer Research, 7, 656-664.
[Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Roy, S., Zhang, B., Lee, V.M.Y., et al. (2005) Axonal Transport Defects: A Common Theme in Neurodegenerative Diseases. Acta Neuropathologica, 109, 5-13.
[Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Cai, Z., Chen, G., He, W., et al. (2015) Activation of mTOR: A Culprit of Alzheimer’s Disease? Neuropsychiatric Disease & Treatment, 11, 1015-1130.
|
|
[58]
|
Caccamo, A., Magrì, A., Medina, D.X., et al. (2013) mTOR Regulates Tau Phosphorylation and Degradation: Implications for Alzheimer’s Disease and Other Tauopathies. Aging Cell, 12, 370-380.
[Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Tang, Z., Bereczki, E., Zhang, H., et al. (2013) Mammalian Target of Rapamycin (mTor) Mediates Tau Protein Dyshomeostasis. Journal of Biological Chemistry, 288, 15556-15570.
[Google Scholar] [CrossRef]
|
|
[60]
|
Caccamo, A., Majumder, S., Richardson, A., et al. (2010) Molecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and Tau: Effects on Cognitive Impairments. Journal of Biological Chemistry, 285, 13107-13120.
[Google Scholar] [CrossRef]
|
|
[61]
|
Spilman, P., Podlutskaya, N., Hart, M.J., et al. (2010) Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer’s Disease, PLoS ONE, 5, e9979.
|
|
[62]
|
Li, L., Zhang, S., Zhang, X., et al. (2013) Autophagy Enhancer Carbamazepine Alleviates Memory Deficits and Cerebral Amyloid-β Pathology in a Mouse Model of Alzheimer’s Disease. Current Alzheimer Research, 10, 433-441.
[Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Qian, L., Yi, L. and Miao, S. (2017) Autophagy and Alzheimer’s Disease. Cellular & Molecular Neurobiology, 37, 1-12.
|
|
[64]
|
Bachurin, S.O., Bovina, E.V. and Ustyugov, A.A. (2017) Drugs in Clinical Trials for Alzheimer’s Disease: The Major Trends. Medicinal Research Reviews, 37, 1186-1225.
[Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
Chalmers, K.A., Wilcock, G.K., Vinters, H.V., et al. (2009) Cholinesterase Inhibitors May Increase Phosphorylated Tau in Alzheimer’s Disease. Journal of Neurology, 256, 717-720.
[Google Scholar] [CrossRef] [PubMed]
|
|
[66]
|
Carter, J. and Lippa, C.F. (2001) Beta-Amyloid, Neuronal Death and Alzhei-mer’s Disease. Current Molecular Medicine, 1, 733-737.
[Google Scholar] [CrossRef] [PubMed]
|
|
[67]
|
Hardy, J. and Selkoe, D.J. (2002) The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics. Science, 297, 353-356.
[Google Scholar] [CrossRef] [PubMed]
|
|
[68]
|
Chance, B., Sies, H. and Boveris, A. (1979) Hydroperoxide Metabolism in Mammalian Organs. Physiological Reviews, 59, 527-605.
[Google Scholar] [CrossRef] [PubMed]
|
|
[69]
|
魏燕, 辛晓燕. 活性氧调控的细胞凋亡信号[J]. 现代肿瘤医学, 2011, 19(2): 371-373.
|
|
[70]
|
Circu, M.L. and Aw, T.Y. (2010) Reactive Oxygen Species, Cellular Redox Systems, and Apoptosis. Free Radical Biology & Medicine, 48, 749-762.
[Google Scholar] [CrossRef] [PubMed]
|
|
[71]
|
Busciglio, J., Lorenzo, A., Yeh, J., et al. (1995) β-Amyloid Fibrils Induce Tau Phosphorylation and Loss of Microtubule Binding. Neuron, 14, 879-888.
[Google Scholar] [CrossRef] [PubMed]
|
|
[72]
|
Khan, A., Vaibhav, K., Javed, H., Khan, M.M., Tabassum, R., Ahmed, M.E., Srivastava, P., Khuwaja, G., Islam, F., Siddiqui, M.S., et al. (2012) Attenuation of Abeta-Induced Neurotoxicity by Thymo-quinone via Inhibition of Mitochondrial Dysfunction and Oxidative Stress. Molecular and Cellular Biochemistry, 369, 55-65.
[Google Scholar] [CrossRef] [PubMed]
|
|
[73]
|
Chen, Y., Huang, X., Zhang, Y., et al. (2012) Alzheimer’s Beta-Secretase (BACE1) Regulates the cAMP/PKA/CREB Pathway Independently of Beta-Amyloid. Journal of Neuroscience, 32, 11390-11395.
|